Interaction between Flurbiprofen (ophthalmic) and Dexamethasone (ophthalmic)
Moderate
Synergy
| ID | DDInter764 and DDInter515 |
| Interaction |
Concomitant use of ophthalmic nonsteroidal anti-inflammatory drugs (NSAIDs) and ophthalmic steroids may increase the potential for healing problems, as both can slow or delay healing.
Arthritis rheumatoid
Bacterial infection
conjunctivitis
corneal disorder
empyema
Eosinophil Count Increased
facial flushing
glaucoma
intestinal perforation
iritis
More
|
| Management | The use of ophthalmic NSAIDs in combination with ophthalmic corticosteroids should be avoided unless benefits outweigh the potential risks. |
| References | |
| Alternative for Flurbiprofen (ophthalmic) |
M02A
More
|
| Alternative for Dexamethasone (ophthalmic) |
R01A
Triamcinolone (nasal)
Tetryzoline (nasal)
Flunisolide (nasal)
Ciclesonide (nasal)
Beclomethasone dipropionate (nasal)
Ipratropium (nasal)
More
|
Potential Metabolism Interactions
Substrate-Substrate Interaction：If more than one drug is metabolized by the same CYP, it is possible that its metabolism is inhibited because of the competition between the drugs. That means, it can be useful to lower the dosage of the drugs in the drug-cocktail because they remain longer in the organism than in monotherapy.
Inhibitor-Inhibitor Interaction：Combining two or more inhibitors of one CYP, should be compensated by lowering the dosage of these drugs because the metabolism is reduced and the drugs remain longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.
Inhibitor-Substrate Interaction：Combining drugs that have inhibitory effect and are substrates of one particular CYP, should be compensated by lowering the dosage. They rest longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.